Moreover, the monoclonal anti-CD38 antibody daratumumab, currently approved for multiple myeloma, has demonstrated renal function improvement in patients with myeloma-related kidney injury, although its application in diabetic nephropathy remains experimental due to potential immune effects [30,31]. This evidence concerns the gene CD38 and AL amyloidosis.